Skip to main content

Table 2 Prevalence of complications at different time periods for the entire cohort (n = 204 patients)

From: Sustained degradation of quality of life in a subgroup of lymphoma survivors: a two-year prospective survey

complications

M0-M3

n (%)

M3-M6

n (%)

M6-M9

n (%)

M9-M12

n (%)

M12-M18

n (%)

M18-M24

n (%)

Infections

51 (25.1)

76 (37.6)

77 (38.3)

71 (35.5)

50 (25.0)

52 (26.1)

Arthralgia

78 (38.2)

80 (39.4)

66 (32.8)

70 (35.0)

53 (26.5)

49 (24.6)

Peripheral neuropathy

50 (24.5)

40 (19.7)

36 (17.9)

32 (16.0)

22 (11.0)

16 (8.0)

Gastritis

20 (9.8)

22 (10.8)

21 (10.4)

14 (7.0)

9 (4.5)

9 (4.5)

Erectile dysfunction

26 (12.7)

26 (12.8)

29 (14.4)

23 (11.5)

23 (11.5)

23 (11.5)

Libido disturbances

26 (12.7)

18 (8.9)

20 (10.0)

15 (7.5)

16 (8.0)

20 (10.0)

Osteoporosis

8 (3.9)

9 (4.4)

8 (4.0)

11 (5.5)

15 (7.5)

11 (5.5)

Hypogammaglobulinemia

50 (24.4)

ND

ND

68 (33.1)

ND

49 (23.9)

Cardio-vascular events

14 (6.8)

9 (4.4)

11 (5.3)

17 (8.2)

16 (7.8)

11 (5.5)

Thyroid (benign)

3 (1.4)

3 (1.4)

3 (1.4)

4 (1.9)

3 (1.4)

3 (1.4)

Urogenitala

14 (6.8)

12 (5.8)

15 (7.5)

11 (5.5)

15 (7.5)

19 (9.2)

Ear, nose and throata

15 (7.5)

8 (3.9)

15 (7.5)

15 (7.5)

8 (3.9)

9 (4.5)

Pulmonarya

19 (9.2)

14 (7.0)

11 (5.3)

17 (8.2)

9 (4.5)

16 (7.8)

Second cancers

3 (1.4)

4 (1.9)

2 (0.9)

3 (1.4)

5 (2.4)

6 (2.9)

  1. a cancers and infections were excluded